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OBJECTIVES: We explored whether high blood pressure is associated with metabolic, inflammatory and
prothrombotic dysregulation in patients with metabolic syndrome.
METHODS: We evaluated 135 consecutive overweight/obese patients. From this group, we selected 75 patients
who were not under the regular use of medications for metabolic syndrome as defined by the current Expert
Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults criteria. The patients were
divided into metabolic syndrome with and without high blood pressure criteria ($130/$85 mmHg).
RESULTS: Compared to the 45 metabolic syndrome patients without high blood pressure, the 30 patients with
metabolic syndrome and high blood pressure had significantly higher glucose, insulin, homeostasis model
assessment insulin resistance index, total cholesterol, low-density lipoprotein-cholesterol, triglycerides, uric acid
and creatinine values; in contrast, these patients had significantly lower high-density lipoprotein-cholesterol
values. Metabolic syndrome patients with high blood pressure also had significantly higher levels of retinol-
binding protein 4, plasminogen activator inhibitor 1, interleukin 6 and monocyte chemoattractant protein 1
and lower levels of adiponectin. Moreover, patients with metabolic syndrome and high blood pressure had
increased surrogate markers of sympathetic activity and decreased baroreflex sensitivity. Logistic regression
analysis showed that high-density lipoprotein, retinol-binding protein 4 and plasminogen activator inhibitor-1
levels were independently associated with metabolic syndrome patients with high blood pressure. There is a
strong trend for an independent association between metabolic syndrome patients with high blood pressure
and glucose levels.
CONCLUSIONS: High blood pressure, which may be related to the autonomic dysfunction, is associated with
metabolic, inflammatory and prothrombotic dysregulation in patients with metabolic syndrome.
KEYWORDS: Hypertension; Sympathetic Activity; Insulin Resistance; Inflammation; Prothrombosis; Metabolic
Syndrome.
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& INTRODUCTION
In 1988, the cardiovascular risk factor cluster, which
includes obesity, increased blood pressure, high triglycer-
ides and glucose and low HDL (high-density lipoprotein)-
cholesterol, was given the name ‘‘metabolic syndrome’’
(MetS) (1). Since then, the scientific community has tried to
better define whether MetS predicts cardiovascular morbid-
ity and mortality better than the sum of the individual
components and whether one component is pivotal over the
others. Most evidence points to visceral obesity and insulin
resistance as central features of MetS. Little attention has
been given to exploring other components of MetS, such as
blood pressure and the potential factors that can influence
not only blood pressure but also the metabolic dysregula-
tion observed in MetS.
Obesity-related sympathetic activation is an attractive
explanation for several components of MetS. In particular,
in 1994, the aggregation of cardiovascular risk factors and
signs of a hyper sympathetic state was demonstrated in the
Tecumseh population (2). Indeed, increased sympathetic
activity (faster heart rate, higher cardiac output and plasma
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noradrenaline) correlated with higher levels of glucose,
insulin, cholesterol, triglycerides, body weight and hemato-
crit and lower levels of HDL-cholesterol. In the Framingham
Heart Study (3), more than 50% of hypertensive patients had
2 or more metabolic abnormalities. Only 19% of males and
17% of females had isolated hypertension. In view of this
finding, the name hypertensive syndrome had been used in
the past (4). However, it is not clear whether the increase in
blood pressure is associated with exacerbations of the
metabolic, proinflammatory, prothrombotic, vascular and
autonomic dysfunctions in patients with MetS.
Evidence suggests that autonomic dysregulation also
contributes to elevated blood pressure and metabolic
abnormalities. Moreover, a1-adrenoceptor antagonists lower
blood pressure, improve insulin sensitivity and ameliorate
dyslipidemia (5). However, it is unclear whether autonomic
dysregulation in metabolic syndrome is associated not only
with hemodynamic impairment but also with metabolic,
inflammatory and other abnormalities associated with the
syndrome. We hypothesized that high blood pressure,
which may reflect increased sympathetic activity, is inde-
pendently associated with metabolic dysregulation and
inflammation in patients with MetS.
& METHODS
Study population
This research was performed at the Heart Institute (InCor)
at the University of Sa˜o Paulo Medical School. Over a 1-year
period, we initially evaluated 135 consecutive overweight or
obese patients from the Sa˜o Paulo metropolitan area. From
this group, we selected 75 patients with MetS, diagnosed
according to ATP III (Third Report of the Expert Panel on
Detection, Evaluation and Treatment of High Blood
Cholesterol in Adults criteria, and with at least three of
the following criteria: high blood pressure - arterial blood
pressure $130 and/or $85 mmHg for systolic and diastolic
blood pressure, respectively; high glucose - fasting glucose
$100 mg/dL; increased waist circumference - $102 cm in
men and$88 in women; increased triglycerides -$150 mg/
dL; decreased HDL -,40 mg/dL in men and ,50 mg/mg/
dL in women) (6). We excluded patients with morbid
obesity (body mass index $40 kg/m2), severe hypertension
(BP .180/110 mmHg), under regular physical activity,
secondary forms of hypertension, diabetes, smokers,
patients with any chronic disease and regularly using
medications (including antihypertensives, see Figure 1).
The patients were divided into 2 groups according to blood
pressure status (patients with MetS without high blood
pressure, i.e., ,130/,85 mmHg: MetS-BP) and (patients
with MetS with high blood pressure, i.e., $130 systolic and/
or $85 mmHg diastolic: MetS+BP).
Clinical evaluation
Patients who fulfilled the criteria for the study underwent
a medical history evaluation. Blood pressure was measured
in triplicate after 5 minutes of seated rest using a calibrated
sphygmomanometer by the same investigator (J.S.G). The
average from 3 blood pressure values was used to define the
presence or absence of the ATP III, the criterion used to
define elevated blood pressure ($130 or $85 mmHg for
systolic and diastolic blood pressure levels, respectively).
Fasting blood samples were drawn for biochemical tests and
cytokine levels. Serum and plasma were obtained and then
stored at -80 C˚. During the second visit, anthropometric
measurements (body mass index – BMI; waist and hip
circumferences; and bicipital, tricipital, subscapular and
suprailiac skinfolds) and fat mass, lean mass, basal
metabolism and total body water were measured using
bioimpedance-measuring equipment (BIA 450, Bio
dynamics, Seattle, USA) (7).
Biochemistry measurements
Total cholesterol, LDL-cholesterol, HDL-cholesterol, tri-
glycerides, uric acid, glucose and creatinine levels were
measured using commercial kits.
Insulin resistance
Insulin resistance was measured using the following 2
methods: the traditional Homeostasis Model Assessment
Insulin Resistance method (HOMA-IR) and the Retinol-
Binding Protein 4 method (RBP4). The HOMA-IR index was
calculated as [fasting serum glucose (mmol/L) x fasting
serum insulin (UI/mL)]/22.5.
Cytokines
Cytokines, including total adiponectin, resistin, leptin,
insulin, interleukin 6 (IL-6), tumoral necrosis factor alpha
(TNF-a), plasminogen activator inhibitor 1 (PAI-1) and
monocyte chemoattractant protein 1 (MCP-1), were mea-
sured using a multiplex sandwich enzyme-linked immuno-
sorbent assay (ELISA, Millipore, MA, USA) (8).
Power spectral analysis
The data for spectral analysis were derived from a finger
pulse contour recorded by beat-to-beat blood pressure
measurements (FinometerH, FMS, Finapres Medical System
BV, Holland) and from the electrocardiogram (ECG) for 10
minutes to characterize the RR interval series. Power
spectral density was obtained by the fast Fourier transfor-
mation, using Welch’s method with a Hanning window of
512 points and 50% overlap as previously described (9). The
entire time, series were previously re-sampled at 5.0 Hz to
be equally spaced in time by a special signal editor
developed for Matlab (MATLAB 6.0; Mathworks, Natick,
Massachusetts, USA). Interpolated time series were deci-
mated to be equally time-spaced. Two main components
were considered for the RR interval variability: low
Figure 1 - Flow diagram used to screen patients.
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frequency (LF; 0.04 to 0.15 Hz) and high frequency (HF; 0.15
to 0.4 Hz). The power density of each spectral component
from the RR interval was calculated in absolute values and
normalized units. The normalized units were obtained by
calculating the percentages of LF variability (LFms2) and HF
variability (HFms2) with respect to the total power after
subtracting the power of very low frequency components
(VLF; frequencies of ,0.04 Hz). The LF/HF ratio was also
calculated to evaluate the sympathovagal balance. In
addition, we also evaluated the power spectral analysis of
systolic BP. Systolic BP spectral powers were quantified in
the LF component (0.04–0.15 Hz) and were reported in
absolute units. LF of systolic BP has been associated as a
reliable marker of sympathetic activity (10).
Baroreflex sensitivity
Beat-to-beat values of systolic BP and RR interval were
used to estimate the cardiac baroreflex sensitivity (BRS) by
spectral analysis, using the alpha index for the low-
frequency band (0.04 to 0.15 Hz). The coherence between
the RR interval and the systolic BP signal variability was
assessed by cross-spectral analysis. The alpha index was
calculated only when the magnitude of the squared
coherence between the RR and systolic BP signals exceeded
0.5 (range 0–1) in the LF band. After coherence calculation,
the alpha index was obtained from the square root of the
ratio between RR and systolic BP variability in the 2 major
LF bands (10-13).
Anxiety and depression evaluation
We performed the Hamilton Scale to assess anxiety (14-
15) and the Beck questionnaire to assess depression (16).
Statistical analysis
The SPSS software (SPSS 10.0, Chicago, IL) was used for
statistical calculations. Data were expressed as the mean-
s¡standard deviations, medians or percentages, as indi-
cated. The Kolmogorov-Smirnov test was used to assess
the normality of distribution of each variable studied.
Categorical variables (sex, race and percentage of MetS
components) were compared using Fisher’s test. Numerical
variables were compared using the unpaired Student’s t test.
Logistic regression analysis (forward model) was used to
identify the metabolic, pro-inflammatory and prothrombotic
markers that were independently associated with the
MetS+BP. The model was controlled for age and BMI.
ANOVA was used to select variables for the logistic
regression analysis. All variables with a p,0.1 in the
univariate analysis were selected for the final model.
P,0.05 was considered to be statistically significant.
Ethics statement
The local ethics committee (Institutional Review Board –
Heart Institute) approved the protocol, which was in
accordance with the ethical standards and with the
Helsinki Declaration of 1975, and all participants gave
written informed consent.
& RESULTS
Figure 1 depicts derivation of the study sample of 75
subjects from the initial sample of 135 patients with MetS.
The percentage of each MetS criterion is reported in the
supplemental file.
Baseline descriptive data on the MetS patients without
(N = 45) and with (N = 30) high blood pressure are provided
in Table 1. We observed a significant trend for increasing
age in the MetS+BP group. There was no significant
difference in gender, % of Caucasians and anthropometric
data, including body mass index, waist circumference, hip
circumference, waist-to-hip ratio, fat percentage as calcu-
lated by skinfold, fat mass, lean mass, metabolic tax and
total body water estimated by bioelectrical impedance
analysis (BIA) (Table 1). As expected, there were significant
differences in the systolic and diastolic blood pressure
measurements between groups. Pulse intervals during
spectral analysis were significantly lower (heart rate faster)
in the MetS+BP compared to the MetS-BP group (Table 2).
The LF components for heart rate and blood pressure and
the LF/HF ratio were significantly higher in the MetS+BP
group than in the MetS-BP group. Baroreflex sensitivity, as
evaluated by the alpha index, was impaired in the MetS+BP
group compared with the MetS-BP group. No differences
were detected between groups with regards to anxiety and
depression (supplemental file).
Table 1 - Demographic, hemodynamic and anthropometric (clinical and bioimpedance) data (means¡sd) in metabolic
syndrome patients without blood pressure criterion (metabolic syndrome - blood pressure) or with blood pressure
(metabolic syndrome + blood pressure).
Variables MetS-BP (n= 45) MetS+BP (n=30) p-value
Age (years) 38¡11 45¡9 0.061
Sex (F/M) 34/11 19/11 0.843
Caucasians, n (%) 32 (71%) 20 (67%) 0.789
Systolic BP (mmHg) 121¡10 144¡18 ,0.0001
Diastolic BP (mmHg) 76¡8 90¡13 ,0.0001
Heart Rate (bpm) 72¡9 77¡12 0.081
Body mass index (kg/m2) 32.2¡4.0 32.5¡4.0 0.767
Waist circumference (cm) 108¡10 (men)/
100¡11 (women)
111¡12 (men)/
101¡11 (women)
0.6 (men)
0.7 (women)
Waist-to-hip ratio 0.93¡0.06 0.95¡0.08 0.265
Fat (%) 32¡6 32¡7 0.817
Fat mass (BIA), % 28¡7 28¡9 0.878
Lean mass (BIA), % 59¡10 60¡13 0.534
BMR (BIA), kcal 1,829¡328 1,842¡398 0.743
TBW (BIA), % 43¡8 44¡10 0.73
BMR=basal metabolic rate; TBW=Total body water.
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Biochemistry data (glucose, total cholesterol, HDL-cho-
lesterol, LDL-cholesterol, triglycerides, uric acid and crea-
tinine), along with insulin and the HOMA-IR index, were
significantly higher in the MetS+BP group than in the MetS-
BP group (Table 3).
RBP4 was significantly higher in the MetS+BP group than
the MetS-BP group (Figure 2A). Leptin, resistin and TNF-a
levels did not differ between the MetS+BP group
(49.4¡41.5 pg/mL, 12.6¡4.6 pg/mL and 4.8¡1.7 ng/mL,
respectively) and the MetS-BP group (41.4¡20.0 pg/mL,
12.9¡4.9 pg/mL and 4.4¡1.4 ng/mL, respectively). IL-6,
PAI-1 and MCP-1, a marker for inflammatory activity, were
significantly higher in the MetS+BP group (Figures 2B-2D).
Adiponectin was lower in the MetS+BP group compared to
the MetS-BP group (Figure 2E). The differences in RBP4,
PAI-1, IL-6, MCP-1 and adiponectin levels between groups
remained significant after adjusting for age and sex.
Logistic regression analysis indicated that HDL, RBP-4
and PAI-1 levels were independently associated with
MetS+BP. There was a strong trend for an independent
association between MetS+BP and glucose levels (Table 4).
& DISCUSSION
Previous studies have shown that patients with MetS
have multiple abnormalities that contribute to increased
cardiovascular risk, including metabolic, proinflammatory,
prothrombotic and autonomic variables (17-19). We
hypothesized that MetS patients with elevated blood
pressure may have greater abnormalities in these same
variables. By stratifying patients with similar obesity levels
according to the presence or absence of high blood pressure,
we found that those with high blood pressure (MetS+BP)
had higher surrogate markers of sympathetic activity
derived from spectral analysis and greater impairment in
several components of MetS, including higher glucose and
triglycerides and lower HDL-cholesterol. The MetS group
with high blood pressure also had higher values for other
risk factors, including total cholesterol, LDL-cholesterol,
uric acid and insulin, along with HOMA index and RBP4,
which are associated with insulin resistance (17,20,21). In
addition, several markers of inflammatory and prothrom-
botic activity, including IL-6, PAI-1 and MCP-1, were
higher, while adiponectin levels were lower in patients
with MetS and high blood pressure. Finally, we found that
HDL-cholesterol, RBP4 and PAI-1 were independently
associated with MetS+BP. Taken together, our results
suggest a significant heterogeneity of the MetS in promoting
metabolic, pro-inflammatory, prothrombotic and autonomic
impairments.
MetS was defined based on the observation that a number
of interrelated characteristics and diseases tended to cluster
in the same individual and contributed to increased
cardiovascular risk. However, MetS is not a well-defined
pathophysiological entity, and the diagnostic criteria are
variable and based on expert opinions (22). The literature
has debated the existence of a major trigger for MetS and its
components or whether the whole is really greater than the
sum of the parts. Obesity emerges as an attractive candidate
to explain all manifestations of MetS, but the best way to
measure this parameter in the MetS scenario is also
debatable. Some studies identified an association between
abdominal obesity (waist circumference) and components of
MetS (23,24), while others showed an association with body
mass index or waist-to-hip ratio (25-28). Regardless of the
obesity parameter, the importance of obesity in inducing
high blood pressure and metabolic and inflammatory
dysregulation is clear.
Elevated sympathetic nervous system activity seems
to be crucial to the development of obesity-related risk
(29). In our study, patients with MetS and high blood
pressure had higher surrogate markers of sympathetic
Table 2 - Power spectral analysis in metabolic syndrome
patients without blood pressure criterion (metabolic
syndrome - blood pressure) or with blood pressure
criterion (metabolic syndrome + blood pressure).
Variable MetS-BP MetS+BP p-value
PI (ms) 887¡120 823¡126 0.1
VAR PI (ms2) 2653¡1910 2578¡1529 0.9
LF (ms2) 638¡607 671¡498 0.9
HF (ms2) 687¡563 590¡549 0.5
LF (%) 48¡15 56¡13 0.04
HF (%) 52¡15 44¡13 0.04
LF/HF 1.0¡0.7 1.5¡0.7 0.08
SBP (mmHg) 126¡13 141¡21 0.003
VAR SBP (mmHg2) 35¡25 50¡25 0.03
LF (mmHg2) 6.7¡4.4 13.0¡9.2 0.001
Alpha index
(ms/mmHg)
10.4¡5.2 7.7¡3.7 0.04
PI = Pulse interval; VAR PI =Variance of PI; LF = low frequency; HF =High
frequency; SBP= Systolic blood pressure; VAR SBP=Variance of SBP.
Table 3 - Biochemical data from metabolic syndrome patients without blood pressure criterion (metabolic syndrome -
blood pressure) or with blood pressure criterion (metabolic syndrome + blood pressure).
Variables MetS-BP (n= 45) MetS+BP (n=30) p-value
Glucose (mg/dL) 97¡8 102¡7 0.013
Insulin (U/mL) 10.5¡3.9 21.5¡20.0 0.007
HOMA-ir 2.5¡1.0 5.4¡5.2 0.006
T-cholesterol (mg/dL) 194¡33 221¡43 0.001
HDL-cholesterol (mg/dL) 40.3¡5.9 (men)/
51.5¡10.6 (women)
38.3¡6.6 (men)/
42.6¡7.6 (women)
0.5 (men) 0.002 (women)
119¡27 145¡39 0.002
Triglycerides (mg/dL) 150¡36 (men)/
124¡54 (women)
190¡78 (men)/
167¡57 (women)
0.2 (men) 0.07 (women)
Uric Acid (mg/dL) 4.6¡1.2 5.6¡1.3 0.001
Creatinine (mg/dL) 0.8¡0.2 1.0¡0.2 0.008
HDL=High-density lipoprotein; LDL= Low-density lipoprotein; HOMA-ir = homeostasis model assessment-estimated insulin resistance index (means¡sd).
Triglycerides values are reported as the medians (interquartile ranges).
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activity. Long-term sympathetic activation can lead to small
artery vasoconstriction and remodeling, which increases the
wall-to-lumen ratio and may act synergistically with large
artery damage to raise blood pressure (30). Sympathetic
activity is also related to baroreflex impairment, as observed
in this study. However, sympathetic activity may not be
related only to hemodynamic impairment but also to
metabolic and inflammatory dysregulation.
In addition to the hemodynamic effects, sympathetically
mediated vasoconstriction may also antagonize insulin-
mediated glucose uptake (29). This theory is supported by
longitudinal studies demonstrating that elevated indices of
sympathetic activation precede the development of insulin
resistance (31). Jamerson et al. showed that norepinephrine
infusion, but not angiotensin, impaired insulin-stimulated
glucose uptake (29-31). In line with the metabolic dysregu-
lation observed in our study, Lichtand et al. found that
autonomic nervous system dysregulation was strongly
associated with MetS and its components in a large cohort
of participants aged 18-65 years (35). However, these
authors did not stratify patients with MetS according to
blood pressure status and did not explore other risk factors
not included in the MetS definition, such as proinflamma-
tory and prothrombotic markers.
In our study, we also observed that adiponectin levels
were lower and that markers of inflammation were higher
in MetS patients with high blood pressure than in MetS
patients without high blood pressure. Sympathetic activa-
tion reportedly reduces adiponectin release, whereas cen-
tral-sympathetic blockade may increase adiponectin levels
(36). Plasma adiponectin is inversely related to insulin
resistance (35). Thus, the increased sympathetic activity in
patients with MetS and high blood pressure may decrease
adiponectin levels that, in turn, can also contribute to
insulin resistance. Systemic inflammation may also be
linked to sympathetic activity. Previous evidence found
that indirect markers of sympathetic activity (increased
heart rate and reduced heart-rate variability) were asso-
ciated with subclinical inflammation in healthy middle-aged
and elderly subjects. These results suggest that an auto-
nomic imbalance in favor of the sympathetic system may
interact with inflammatory processes to play a more
important role in the process of vascular stiffness and
atherosclerosis.
A few limitations from this investigation should be
addressed. First, due to the study design, our findings
suggest an association rather than a cause-effect relationship
between high blood pressure and metabolic, inflammatory,
prothrombotic and autonomic impairments in patients with
MetS. Although consistent with the cited literature, we
cannot prove that sympathetic activity is the main obesity-
related trigger underlying not only the increased blood
pressure but also impairments in the metabolic, inflamma-
tory and prothrombotic profiles in this subgroup of patients
with MetS. Second, direct measurements of peripheral
sympathetic activity using microneurography were not
performed. However, spectral analysis is an acceptable
non-invasive method for estimating sympathovagal activity
(13). Our findings consistently suggest a decrease in vagal
activity and the activation of the sympathetic system in the
spectral analyses of both heart rate and blood pressure.
Third, these results cannot be extrapolated to MetS patients
with diabetes. Finally, the precise reasons by which a subset
Table 4 - Logistic regression analysis for variables
independently associated with metabolic syndrome with
high blood pressure (metabolic syndrome + blood
pressure)
Variables B Sig. OR 95% C.I. for OR
Lower Upper
GLIC 0.118 0.057 1.125 0.996 1.270
HDL -0.147 0.008 0.863 0.775 0.962
RBP4 1.507 0.001 4.511 1.909 10.663
PAI1 0.270 0.002 1.311 1.103 1.558
Constant -20.148 0.011 0.000
Figure 2 - Retinol-binding protein 4 levels (2A), plasminogen activator inhibitor 1 levels (2B), interleukin 6 levels (2C), monocyte
chemoattractant protein 1 levels (2D) and adiponectin levels (2E) in metabolic syndrome - blood pressure and metabolic syndrome +
blood pressure subjects. The results are presents as the means¡SD.
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of patients with MetS had higher blood pressure and greater
sympathetic activity despite similar indices of obesity are
not clear. Recent studies reported the potential role of
psychosocial stress in inducing sympathetic activity
(29,37,38). Another potential candidate is obstructive sleep
apnea. This clinical condition is characterized by sympa-
thetic activation that is independent of obesity, and it is a
well-established cause of high blood pressure and increased
arterial stiffness (39-41). Recent evidence in consecutive
patients with MetS suggests that obstructive sleep apnea is
quite common and is independently associated with
increased sympathetic activity (41), metabolic and inflam-
matory dysregulation (42) and increased markers of athero-
sclerosis (43). These potential confounders should be
addressed in future investigations.
In conclusion, this study provides several provocative
new findings that suggest the importance of characterizing
patients with MetS according to the presence or absence of
high blood pressure. Although we cannot prove a cause-
effect relationship, our results demonstrated that patients
with MetS and high blood pressure have higher surrogate
markers of sympathetic activity and significant metabolic,
inflammatory and prothrombotic impairments. Thus, it is
reasonable to speculate that blocking sympathetic activity is
an attractive strategy for treating patients with MetS. A
previous study showed that a combined a- and b-adrenergic
blockade significantly reduced blood pressure in obese
patients compared to lean patients with essential hyperten-
sion (44). Moreover, renal denervation, which reduces
sympathetic activity, lowers blood pressure and reduces
insulin resistance, may improve obstructive sleep apnea
(45). Future studies will clarify whether pharmacological
suppression of sympathetic activity in patients with MetS
will improve not only blood pressure but also the metabolic,
inflammatory and prothrombotic dysfunctions observed in
these patients.
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